The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.

Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.

The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.

And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.

The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.

AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.